Caribou Biosciences reports Q2 2026 results: $1.5M licensing revenue, $24.3M GAAP net loss
Caribou Biosciences reported its Q2 2026 financial results, showing $1.5 million in licensing revenue and a GAAP net loss of $24.3 million. The company holds $113.8 million in cash and expects these funds to support operations through the end of 2027. Business highlights include …